David Bonita is a physician-investor at OrbiMed Advisors who trained as an M.D. at Harvard Medical School and completed clinical work at Massachusetts General Hospital before moving into investing, giving him first-hand understanding of oncology and complex therapeutics. He has spent over two decades at OrbiMed, growing from private equity associate to General Partner in 2020, and invests across both private and public healthcare companies while serving on boards at oncology and therapeutics companies such as Prelude Therapeutics, Repare Therapeutics, and Mirador Therapeutics. David Bonita is a physician-investor at OrbiMed Advisors who trained as an M.D. at Harvard Medical School and completed clinical work at Massachusetts General Hospital before moving into investing, giving him first-hand understanding of oncology and complex therapeutics. He has spent over two decades at OrbiMed, growing from private equity associate to General Partner in 2020, and invests across both private and public healthcare companies while serving on boards at oncology and therapeutics companies such as Prelude Therapeutics, Repare Therapeutics, and Mirador Therapeutics.